Current role
Drug Manufacturers - Specialty & Generic · Healthcare
Chairman, Board Member
2018-01-01–present
Cheryl R. Blanchard
Chairman
Anika Therapeutics, Inc. (ANIK)Board Member
Anika Therapeutics, Inc. (ANIK)Equibles does not estimate personal net worth.
Get an email with a short summary when Anika Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ANIK alertsAbout Cheryl R. Blanchard
Cheryl R. Blanchard is recorded as Chairman at Anika Therapeutics, Inc. (ANIK) since February 1, 2026 and Board Member at Anika Therapeutics, Inc. (ANIK) since January 1, 2018. The newest filing on record that lists Cheryl R. Blanchard as Board Member at Anika Therapeutics, Inc. (ANIK) is dated April 28, 2026. Anika Therapeutics, Inc. reported in an 8-K filed January 8, 2026 that Cheryl R. Blanchard was appointed Executive Chair, effective February 1, 2026. Anika Therapeutics, Inc. reported in an 8-K filed June 24, 2025 a re-election or new board role (Class II director) for Cheryl R. Blanchard, on the board since at least 2018, effective June 20, 2025. The proxy statement of Anika Therapeutics, Inc. reports total compensation of $4,887,318 for Cheryl R. Blanchard in fiscal 2025, including a base salary of $750,397. Disclosed compensation is on record for 8 fiscal years. Anika Therapeutics, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Anika Therapeutics, Inc. includes Cheryl Blanchard (CEO and Board Member), Stephen (Steve) Griffin (CEO and Board Member), Stephen D. Griffin (CEO, CFO and Board Member) and 7 others.
“Dr. Blanchard will transition into the role of Executive Chair of the Company's Board of Directors ("Board") for a period of twelve (12) months through January 31, 2027.”
“As a result of this vote, Dr. Blanchard, Mr. Capper and Dr. Larsen were elected as Class II directors to serve until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until his or her earlier resignation or removal.”
Affiliation history
-
Current
2026-02-01–present
-
Current
2018-01-01–present
Last confirmed April 28, 2026
-
Anika Therapeutics, Inc. (ANIK)
Proxy statement
CurrentStart not stated–present
Last confirmed April 28, 2026
-
Start not stated–2025-04-28
Last confirmed by a filing; no departure on record
Company network
Leadership on record at Anika Therapeutics, Inc.
- Cheryl Blanchard CEO, Board Member
- Stephen (Steve) Griffin CEO, Board Member
- Stephen D. Griffin CEO, CFO, Board Member
- Steve Griffin CEO, Board Member
- Jeffery S. Thompson Chairman
- John B. Henneman, III Chairman, Board Member
- Michael Levitz CFO
- Stephen Griffin CFO
- Anne Nunes COO
- David B. Colleran General Counsel
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Anika Therapeutics, Inc. (ANIK) | Executive Chair; Former President and Chief Executive Officer | $750,397 | $4,887,318 |
| 2024 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer | $743,943 | $5,103,466 |
| 2023 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer | $726,000 | $4,459,800 |
| 2022 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer | $695,100 | $5,940,722 |
| 2021 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer | $668,400 | $4,202,608 |
| 2020 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer | $548,077 | $10,029,434 |
| 2019 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer | — | — |
| 2018 | Anika Therapeutics, Inc. (ANIK) | President and Chief Executive Officer | — | — |